Discounted Cash Flow (DCF) Analysis Unlevered

Forward Pharma A/S (FWP)

$2.8523

-0.07 (-2.32%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 2.8523 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1,250---------
Revenue (%)
EBITDA 1,184.71---------
EBITDA (%)
EBIT 1,184.49---------
EBIT (%)
Depreciation 0.23---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash 109.55---------
Total Cash (%)
Account Receivables 0.94---------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable 1.20---------
Accounts Payable (%)
Capital Expenditure -0---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 2.8,523
Beta 1.381
Diluted Shares Outstanding 6.98
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.010
Total Debt -
Total Equity 19.92
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1,250---------
EBITDA 1,184.71---------
EBIT 1,184.49---------
Tax Rate 22.57%2.29%0.00%0.00%0.00%4.97%4.97%4.97%4.97%4.97%
EBIAT 917.09---------
Depreciation 0.23---------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0---------
UFCF 917.32---------
WACC
PV UFCF ---------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -70.77
Equity Value -
Shares Outstanding 6.98
Equity Value Per Share -